V114 Pneumococcal Vaccine Has Acceptable Safety Profile for Infants
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 13, 2023 -- VAXNEUVANCE (V114), the 15-valent pneumococcal conjugate vaccine (PCV) containing the 13 serotypes in Prevnar 13 (PCV13) plus serotypes 22F and 33F, is well-tolerated and safe for infants, according to a study published online June 13 in Pediatrics.
Natalie Banniettis, M.D., from Merck & Company in Rahway, New Jersey, and colleagues examined the safety and tolerability of V114 in a phase 3 study involving 2,409 infants who were randomly assigned to receive V114 or PCV13 at ages 2, 4, 6, and 12 months.
The researchers found that recipients of V114 and PCV13 generally had comparable proportions with injection-site, systemic, vaccine-related, and serious adverse events (AEs). The most frequently reported AEs were solicited; in both groups, irritability and somnolence were the most frequent AEs. The incidence of some AEs was higher in the V114 group, but the differences between groups were small. Most AEs were of mild-to-moderate intensity and had a duration of no more than three days. In the V114 group, there were two vaccine-related serious AEs of pyrexia reported; one non-vaccine-related death occurred in each group. None of the participants discontinued the study vaccine due to AEs.
"Data from this trial suggest V114 has an acceptable safety profile and is well-tolerated among healthy infants," the authors write. "Overall, findings support the use of V114 in pediatric vaccination programs."
Several authors disclosed ties to pharmaceutical companies, including Merck, which manufactures VAXNEUVANCE and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Slight Body Mass Gains in Middle Age May Cut Later Fracture Risk
FRIDAY, May 17, 2024 -- People whose body mass index (BMI) slightly increases from normal weight to low-level overweight during 30 years of middle adulthood have a lower risk for...
High Level of Approval Observed for Polygenic Embryo Screening
FRIDAY, May 17, 2024 -- There is a high level of approval for use of polygenic embryo screening, according to a study published online May 14 in JAMA Network Open. Rémy A...
AI Chatbots Can Generate Quality, Empathetic, Readable Responses
FRIDAY, May 17, 2024 -- For patient questions about cancer, artificial intelligence (AI) chatbots can generate quality, empathetic, and readable responses, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.